Dell Technologies Inc. (NYSE: DELL): What EMC’s $984.3 m Air Force award means for defense IT strategy
Read More Pharma Industry News Will CABOMETYX secure EU approval for advanced neuroendocrine tumors after CHMP’s positive opinion? Ipsen’s CABOMETYX receives EMA's CHMP backing for advanced neuroendocrine tumors; EU approval expected in 2025 following FDA nod. byPallavi MadhirajuJune 24, 2025